Therapeutic potential of sglt-2 inhibitors and ddp4 inhibitors in elderly patients with type 2 diabetes mellitus and benign prostatic hyperplasia

HIGHLIGHTS

• What: The aim of this study is to compare the impact of either a DPP-4 inhibitor or an SGLT-2 inhibitor on prostate volume progression and symptoms. The authors report that the use of either SGLT-2 inhibitors or DPP-4 inhibitors in the management of patients with T2DM and BPH results in favorable outcomes on prostate volume and prostate symptoms, consequently improving sleep quality, as expressed by the Pittsburgh Sleep Quality Index (PSQI). The authors report the effect of these two novel anti-hyperglycemic agents on prostate symptoms as assessed by the international prostate symptoms . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.